

To,

The Manager
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting under regulation 30 read Schedule III of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Ref:Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Sangam Health Care Products Limited held on Friday, the 26th day of May at 12.30 P.M. at the registered office of the Company the following were duly considered and approved by the Board:


1. Audited Financial Results for the quarter and Year ended 31.03.2020.
2. Auditors' Report for the quarter & year ended 31.03.2020.
3. Appointment of Secretarial Auditor for the financial year 2020-21.
4. Appointment of Internal Auditor for the financial year 2020-21.
5. Resignation of Mr. Khushwant Singh as Independent Director of the Company.
6. Resignation of Mr. Ramu Chaganti as Independent Director of the Company.

The meeting of the Board of Directors commenced at 12.30 P.M (IST) and concluded at 2-30 P.M (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Sangam Health Care Products Limited



A. Bala Gopal
Managing Director
(DIN: 01712903)



To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001

Date: 26.06.2020

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

Ref: Scrip Code –531625

I, A. Bala Gopal, Managing Director of M/s. Sangam Health Care Products Limited hereby declare that, the Statutory Auditors of the company, M/s. M.M Reddy & Co., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2020.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide. Circular No. No.CIR/CFD/CMD/56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,

For Sangam Health Care Products Limited



A. Bala Gopal
Managing Director
(DIN: 01712903)

SANGAM HEALTH CARE PRODUCTS LIMITED						
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & ENDED MAR 31, 2020						
Sl No.	Particular	Quarter ended			Year ended	
		31.03.2020 [Un-audited]	31.12.2019 [Un-audited]	31.03.2019 [Un-audited]	31.03.2020 [Audited]	31.03.2019 [Audited]
1	Revenue from Operations	395.82	609.1	483.46	2180.55	2,103.92
2	Other income	-313.53	0	4.03	1.78	4.03
	Total Income	82.29	609.1	487.49	2182.33	2107.95
3	Expenses:					
	Material consumed	173.36	312.17	204.4	1024.09	1041.49
	Changes in inventories	-82.2	-23.06	-52.47	-39.29	-125.85
	Employees benefit expenses	66.76	233.47	169.98	552.44	539.76
	Depreciation & amortization expenses	11.42	42.53	36.14	125.54	150.26
	Other expenses	98.81	81.62	211.66	469.5	763.12
	Total Expenses	268.15	646.73	569.71	2132.28	2368.78
4	Profit before exceptional and extraordinary items and tax (3 - 4)	-185.86	-37.63	-82.22	50.05	-260.83
5	Exceptional items	-291.54	0	-42.76	-291.54	-42.76
6	Profit before tax	105.68	-37.63	-39.46	341.59	-218.07
7	Tax expense:				0	
	(1) Current tax	0	0	0	0	0
	(2) Deferred tax	63.84	0	15.27	63.84	-15.27
8	Net Profit After Tax	41.84	-37.63	-54.73	405.43	-202.8
9	Other Comprehensive Income					
A	Items that will not be reclassified to statement of Profit & loss:					
	i) remeasurement benefits for the define benefit plans	-	-	-	-	-
	ii) equity instrumcments thorough other comprehensive income	-	-	-	-	-
	iii) Defered tax relating to the above items	-	-	-	-	-
B	Net fair value loss on instrument in equity instruments thorough OCI	41.84	-37.63	-54.73	405.43	-202.8
	Total Other Comprehensive Income /loss					
11	Total Other Comprehensive Income					
12	Paid-up Equity share capital	1486	1486	1486	1486	1486
13	Other Equity	0	0	0	0	-3483.36
14	Earnings per equity share:					
	(i) Basic					
	(ii) Diluted	-0.51	-0.0253	-0.51	0	-1.36

NOTES:

- The above mentioned financial results have been reviewed by the Audit Committee and approved by the board of directors at meeting held 26th June,2020





SANGAM HEALTHCARE PRODUCTS LIMITED **Saf**

(ISO 9001 Certified Company)

CIN L24230TG1993PLCO16731

- 2 in accordance with the requirement of regulation 33 of the SEBI (listing obligation and disclosure requirement) regulation 2015 the statutory auditor have performed review of the above audited financials results for quarter and year ended 31 march,20
- 3 The figures of quarter ended 31st march are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
- 4 The Company operates in Single Business Segment therefore Segment reporting is not applicable to the Company
- 5 The statement has been prepared in accordance with companies (Indian Accounting Standards) Rules, 2015 (Ind AS). Prescribed u/s133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 6 The adoption in Ind AS 115 "Revenue from Contracts with Customers", with effect from April,2018 did not have any significant impact to the financial results of the Company.
- 7 Previous period figures are regrouped, rearranged, where ever necessary. The Company has only one Segment.

For Sangam Health Care Products Limited

A. Balagopal

Director

DIN: 01712903

Place: Hyderabad

Date: June,26, 2020



S.No	Statement of Assts and Liabilites	As at 31.03.20 Audited	As at 31.03.19 Audited
1	Assets		
	1) Non Current Assets		
	a) Property, Plant & Equipments	624	1865
	b) intangible Assets		
	c) Capital Work in Process		
	d) financial Assets		
	Investments		
	Loans		
	e) Deffered Tax Assets		
	f) Other Non current Assets	34	34
	2) Current Assets		
	a) Inventories	371	277
	b) Financial Assets		
	Trade Receivables	50	35
	Cash and Cash Equivalents	1	5
	Short Term Loans & Advances	217	161
	Other Current Assets		
	TOTAL ASSETS	1296	2377
2	EQUITY AND LIABILITIES		
	1)EQUITY		
	a) Share Capital	1486	1486
	b) Other Equity	-3078	-3483
	Total Equity	-1592	-1997
	2) Non-Current Liabilities		
	a) Financial Liabilities Borrowings	48	78
	b) Deffered Tax Liabilities	69	133
	c) Long Term Provisions	68	70
	Sub- Non-current Liabilities	185	281
	3) Current Liabilities		
	A) Financials		
	i) Short term Borrowings	1711	2036
	ii) Trade Payable	592	400
	iii) Other financial Liabilities	400	258
	B) Other Current Liabilities	0	1400
	c) Provisions		
	d)Current Tax Liabilities		
	Sub- Current Liabilities	2703	4093
	Total Equity and Liabilities	1,296	2,377

For Sangam Health Care Products Limited

A. Balagopal

A. Balagopal

Director

DIN: 01712903

Place: Hyderabad

Date: June,26, 2020



CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 31st March, 2020

Particulars	31-03-2020 (₹)	31.03.2019 (₹)
A. CASH FROM OPERATING ACTIVITIES		
(Loss)/Profit before tax and extraordinary items	5,003,971	(26,084,113)
Adjustment for		
- Depreciation	12,554,622	15,026,427
- Interest & Financial charges	2,945,392	20,996,439
- Other Income	(177,618)	(403,647)
Operating Profit before Working Capital Changes	20,326,367.	9,535,106
Adjustment for		
- Trade & Other receivables	(1,541,141)	(3,385,933)
- Inventories	(9,393,372)	(18,729,929)
- Trade & others Payable	33,488,930	(68,504,672)
- Short term Loans & Advances	(5,582,439)	256,054
- Short Term Borrowings & Provisions	(172,517,467)	187,835,773
Cash flow before Extraordinary items	(135,219,121)	107,006,399
- Interest paid	(2,945,392)	(20,996,439)
- Taxes paid	-	(736,342)
Net Cash flow before extraordinary items	(138,164,514)	85,273,618
-Extraordinary & Prior period items	29,154,304	4,276,702
NET CASH FROM OPERATING ACTIVITIES	(109,010,210)	89,550,320
B. CASH FROM INVESTING ACTIVITIES:		
Purchase of Fixed Assets	111,576,993	(2,267,008)
Other Income	177,618	403,647
Long Term Loans & Advances	-	(8,375,898)
NET CASH FROM INVESTING ACTIVITIES	111,754,611	(10,239,259)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long Term Borrowings	(3,000,000)	(80,000,000)
Long Term Provisions	(181,840)	(498,674)
NET CASH FROM FINANCING ACTIVITIES	(3,181,840)	(80,498,674)
NET INCREASE IN CASH & CASH EQUIVALENTS	(437,439)	(1,187,613)
Opening Cash and cash equivalents	512,575	1,700,188
Closing Cash and Cash equivalents	75,136	512,575

**For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED**

(Signature)
BalaGopal Addepalli
Managing Director
DIN No.01712903



Place: Hyderabad
Date : 26-06-2020



Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

**To the Board of Directors of Sangam Healthcare Products Limited
Report on the Audit of Standalone Financial Results**

Opinion

We have audited the accompanying standalone annual financial results of Sangam Healthcare Products Limited hereinafter referred to as 'the Company' for the quarter and year ended March 31, 2020 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the company for the yearended March 31, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.



We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results


Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to



fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.




- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fairpresentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For M M REDDY & CO.,
Chartered Accountants
Firm Registration No.0103718



CA M. Madhusudhana Reddy
Partner
Membership No.213077
UDIN: 20213077AAAAFH9165



Date: 26-06-2020
Place: Hyderabad